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Background: To examine fracture incidence in women with rheumatoid arthritis (RA) for an entire geographical
region of south-eastern Australia.
Methods: Women aged 35 years and older, resident in the Barwon Statistical Division (BSD) and clinically
diagnosed with RA 1994–2001 were eligible for inclusion as cases (n = 1,008). The control population (n = 172,422)
comprised the entire female BSD population aged 35 years and older, excluding those individuals identified as
cases. Incident fractures were extracted from the prospective Geelong Osteoporosis Study Fracture Grid. We
calculated rate ratios (RR) and 95% confidence intervals (CI) to compare the age-adjusted rate of fracture between
the RA and non-RA populations, and used a chi-square test to compare proportions of fractures between women
with and without RA, and a two-sided Mann–Whitney U-test to examine age-differences.
Results: Among 1,008 women with RA, 19 (1.9%) sustained a fracture, compared to 1,981 fractures sustained by the
172,422 women without RA (1.2%). Fracture rates showed a trend for being greater among women diagnosed with
RA (age-adjusted RR 1.43, 95%CI 0.98-2.09, p = 0.08). Women with RA sustained vertebral fractures at twice the
expected frequency, whereas hip fractures were underrepresented in the RA population (p < 0.001). RA status was
not associated with the likelihood of sustaining a fracture at sites adjacent to joints most commonly affected by RA
(p = 0.22).
Conclusion: Given that women with RA have a greater risk of fracture compared to women without RA, these
patients may be a suitable target population for anti-resorptive agents; however, larger studies are warranted.
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Previous investigations regarding fracture risk in women
with rheumatoid arthritis (RA) have been confined to spe-
cific sub-populations or a limited number of fracture sites:
there is currently little known regarding the overall risk
of fracture associated with RA.
Women with RA have an increased risk of fracture
compared to women without RA.
Fractures are more likely to occur at major osteoporotic
sites than at sites adjacent to the joints affected by RA.
Women with RA may be a suitable target population
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Rheumatoid arthritis (RA) is an autoimmune disease
characterised by symmetric joint inflammation, stiffness
and pain, and by muscular weakness around the affected
joints. RA is the most severe form of arthritis [1]. The
worldwide prevalence of RA is approximately 1%, and the
most prevalent autoimmune condition in Australia, affect-
ing 2.1% of the population, 63% of whom are women [1].
The onset of RA generally occurs between 40–60 years of
age, peaking in females aged 65–74 years [1].
Drug therapies in RA are aimed at maintaining or
improving functional status, and the more commonly
prescribed anti-inflammatory drugs in the treatment of
RA include non-steroidal anti-inflammatory drugs (NSAIDs)
or glucocorticoid therapy; the latter used in cases of active
and severely disabling RA [2]. A well-documented effectl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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causing an increase in bone resorption and a decrease in
formation via several different mechanisms [2]. However,
glucocorticoids are also potent immunosuppressants and
can therefore reduce bone damage associated with disease
activity in RA [3,4].
Bone loss in RA can also occur independently of cor-
ticosteroid therapy, and the localised erosion of bone
around disease joints is a characteristic of RA [5]. Whilst
osteoclastogenesis is induced in the RA inflammatory
response [6,7] resulting in bone resorption, some erosions
of bone appear to be physically rather than chemically me-
diated [8]. Generalised skeletal bone loss is also associated
with RA. Studies have shown that bone mineral density
(BMD) at the hip and spine is lower in RA patients com-
pared to the general population [6,9,10]. It is plausible that
a number of different factors associated with RA may be
involved in the process of generalised bone loss. Disease
activity and duration, and corticosteroid use have been
implicated in bone loss at both the hip and spine whereas
studies suggest decreased physical activity may be only
associated with decreased hip BMD [3,6,10,11].
The presence of these factors, in combination with older
age, suggests that RA patients may be a population at in-
creased risk of fracture; an association reported by some
studies [12-14]. However, given that many previous inves-
tigations have been confined to specific sub-populations,
small sample sizes, or a limited number of fracture sites,
there is currently little known regarding the overall risk
of fracture associated with RA. We aimed to examine;
(a) whether fracture incidence would differ between women
with RA and women without RA, and (b) whether the
site-specific fracture would differ between women with
and without RA, using an entire statistical division of
south-eastern Australia as the study population.
Methods
Rheumatoid arthritis (cases)
Women aged 35 years and older, resident in the Barwon
Statistical Division (BSD), and with RA diagnosis between
1994 and 2001 were eligible for inclusion in these analyses.
RA status was ascertained by manually checking the eligi-
bility criteria (age, sex, and resident status) against records
of the Barwon Rheumatology Service, the region’s sole
rheumatology practice that was established in the early
1990s. RA was diagnosed by the treating rheumatologists
at the Barwon Rheumatology Service, Victoria, Australia,
using the predominant diagnostic set of criteria published
by the American Rheumatism Association in 1988 [5].
Non-RA population (controls)
The control population comprised the entire BSD popula-
tion aged 35 years and older, excluding those individuals
identified in the RA population, in order to provide twomutually exclusive groups for case–control analyses. The
1996 Australian Bureau of Statistics (ABS) Census count
for the BSD female population aged 35 years and older
was 57,454 [15]. Control population figures for the years
of 1994 and 1995 were extrapolated using the 1996
population figures.Ascertainment of incident fracture
The Geelong Osteoporosis Study (GOS) Fracture Grid
(GOS-FracGrid) prospectively documents all incident
fractures sustained by residents of the BSD using a vali-
dated method to identify fractures from original radio-
logical reports, as previously published [16]. The first
occurring incident fracture for all women in the BSD aged
35 years and older was identified for a two year period
1994–96 [15]. To calculate the RA population fracture
incidence rate in person-years, fractures occurring in the
RA population 1994–1996 were used, in order to examine
whether the fracture incidence in women with RA was
increased compared to women without RA. The GOS-
FracGrid uses the International Classification of Diseases,
Ninth Revision (ICD-9) [17] to code the site of fracture, as
previously published. In order to increase the sample size
to examine site-specific fractures, we included every
fracture case that occurred from 1994–2001 for analyses,
although where multiple fractures, only the first fracture
at any individual site was included.
Approval for this study was provided by the Barwon
Health Human Research and Ethics Committee (HREC).
For the RA cases, written informed consent to access
fracture records was provided by living patients, and
Barwon Health HREC provided ethical approval to access
the electronic medical records of patients with RA that
were deceased. Development of the comprehensive GOS-
FracGrid was approved via a waiver of consent provided
by Barwon Health HREC.Statistical analyses
Age- and sex-specific, total-fracture and site-specific
fracture incidence rates in person years for the entire
BSD population have been published using the data col-
lected by GOS 1994–1996 [18]; the corresponding rates
for the non-RA population included in our current study
were derived from those data by removing the individuals
with RA. We made the assumption that fracture rates
remained constant between 1994–2001 and this assump-
tion was used to calculate the expected fracture numbers
in the RA cases.
Age-adjusted rate ratios (RR) and 95% confidence in-
tervals (CI) were calculated to compare the rate of inci-
dent fracture between women with and without RA.
When calculating the age-adjusted RR, the following
categorical age groupings were used; 35–54 years, 55–
Table 2 Numbers of fractures in women with and without
RA (1994–96) in the Barwon Statistical Division, stratified













1994 319 3 (0.94%) 57,491 601 (1.04%)
1995 333 5 (1.50%) 57,477 690 (1.20%)
1996 356 11 (3.09%) 57,454 690 (1.20%)
Total 1,008 19 (1.88%) 172,422 1,981 (1.15%)
*Control population figures were extrapolated using 1996 Census data [15].
**Raw fractures figures were ascertained for 1994–1996 from Sanders et al. [18].
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stratum held an appropriate number of fractures.
To examine site-specific fracture and RA, we used a
chi-square test to examine differences in proportions of
fractures between the two groups, and a two-sided Mann–
Whitney U-test was used to examine age-differences.
All analyses were performed using Minitab (Version
12.0; Minitab, State College, PA).
Results
Mean age for RA cases was 64 years (IQR 52–71) and
53 years (IQR 43–68) for the non-RA population. A
Mann–Whitney test revealed that the median age for
RA cases was older than that of the control population
(T = 9.2, p < 0.001). At the onset of RA, mean (± SD) age
was 53 ± 16 years, and the year of RA onset ranged between
1940 and 2001, with the majority of RA patients developing
the disease post-1989. The prevalence of RA in women
was 0.6%.
Fracture incidence
Table 1 presents the number and percentage of fractures
according to skeletal site, in women with and without
RA. Table 2 presents the numbers of fractures sustainedTable 1 Number and percentage of fractures by skeletal





Face 1 (1.2%) 13 (0.8%)
Skull 0 2 (0.1%)
Vertebra 26 (31.7%) 243 (15.6%).
Rib 4 (4.9%) 64 (4.1%)
Pelvis 2 (2.4%) 63 (4.0%)
Clavical 0 14 (0.9%)
Scapula 0 7 (0.5%)
Humerus 12 (14.6%) 128 (8.2%)
Forearm 3 (3.7%) 108 (6.9%)
Colles’ 6 (7.3%) 211 (13.5%)
Carpal bone 1 (1.2%) 18 (1.2%)
Hand 1 (1.2%) 23 (1.5%)
Finger 1 (1.2%) 36 (2.3%)
Hip 6 (7.3%) 321 (20.5%)
Upper leg 4 (4.9%) 25 (1.6%)
Patella 4 (4.9%) 21 (1.3%)
Lower leg 3 (3.7%) 85 (5.4%)
Ankle 4 (4.9%) 100 (6.4%)
Foot 3 (3.7%) 55 (3.5%)
Toe 1 (1.2%) 26 (1.7%)
Total 82 (100%) 1563 (100%)by women with and without RA for the study period of
1994–1996 in the BSD, stratified by year of data ascer-
tainment. Of the 1,008 women with RA, 19 (1.9%) sus-
tained a fracture compared to 1,981 fractures sustained
by the 172,422 women without RA (1.2%).
Crude fracture incidence rates for women with and
without RA were 188 per 10,000 person years and 114
per 10,000 person years, respectively. In age-adjusted
analyses, a trend was observed for women with RA to
be 43% more likely to fracture than non-RA women of
the same age (age-adjusted RR 1.43, 95%CI 0.98, 2.09,
p = 0.08).
Site-specific fracture
In women with RA, 82 fractures were sustained during
the study period, whereas 1,563 fractures were sustained
by the non-RA group (Table 3). No age-differences at time
of fracture were observed between women with RA or in
women without RA (72 vs.74 years, respectively, U-1.00,
95%CI −2.00, 4.00, p = 0.38).
The proportions of classic ‘osteoporotic’ fractures
(Colles’, vertebral, and hip) sustained by the RA and non-
RA groups differed significantly (χ2 = 21.71, p < 0.001).
The greatest difference between observed and expected
values occurred for the vertebral and hip fractures,
whereby women with RA sustained vertebral fractures at
twice the expected frequency (26.0% versus 13.4), whereas
hip fractures were underrepresented in the RA population
(6% versus 16.3) (χ2 = 21.71, p = <0.001). No difference
was observed between the RA and non-RA groups in the
likelihood of sustaining a fracture at sites adjacent to the
joints most commonly affected in RA (χ2 = 3.02, p = 0.22).
Discussion
Our data show a greater risk of fracture for women with
RA compared to non-RA women, with no age difference
at the time of fracture regardless of RA status. Fractures
are more likely to occur at major osteoporotic sites such
as vertebral, hip or Colles’ , than at sites adjacent to the
joints affected by RA.
Table 3 Observed and expected number of fractures at primary osteoporotic sites, and sites adjacent to the joints
most commonly affected early in RA in the Barwon Statistical Division
Rheumatoid arthritis (cases) Non-rheumatoid arthritis (controls) Chi-square test
Observed Expected Observed Expected χ2 value p value
Primary osteoporotic sites
Vertebral 26 13.4 243 255.6 21.71 <0.001
Colles’ 6 10.8 211 206.2
Hip 6 16.3 321 310.7
Other 44 41.5 788 790.5
Sites adjacent to joints most commonly affected early in RA
Colles’/Carpal/Hand/Fingers 9 14.8 288 282.2 3.02 0.22
Foot/Toes 4 4.2 81 80.8
Other 69 63.0 1,194 1200
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commonly affected in RA, and therefore the regions more
likely to have suffered localized bone erosion resulting in
low BMD. In the general female population, fractures at
these sites most commonly occur in females aged less than
50 years [18,19]. It is plausible that in females with RA,
the most influential risk factors for fracture are the same
as those factors which predispose non-RA women to
fracture, for instance menopausal status and age, rather
than disease specific factors such as RA disease activity
or duration; a suggestion supported by others [13,20].
We may also speculate that localized bone erosion around
joints affected by RA has less influence of the risk of
fracture compared to the reduced BMD seen at the hip
and spine in RA patients.
In our study, women with RA sustained vertebral frac-
tures at twice the expected frequency; consistent with
other studies that examined associations between vertebral
fractures and RA [14,21,22]. The most plausible explan-
ation for this is the increased rate of detection of vertebral
fractures, rather than a true increase in incidence. It has
been estimated that approximately two thirds of vertebral
fractures are asymptomatic [23,24], resulting in many ver-
tebral fractures in the general population remaining un-
diagnosed. In contrast, RA patients have overall poorer
health [25,26], with a consequent increase in the likelihood
for incidental detection of asymptomatic vertebral
fractures. However, in a case–control study of Norwe-
gian females, those with RA were more likely to have
at least one vertebral deformity compared to those
without RA (22% vs. 15%), and significantly more likely
to have multiple vertebral deformities (11% vs. 5%, re-
spectively). The presence of deformities is important,
given they have been associated with subsequent frac-
ture [14,27]. Importantly, our data are in the majority
consistent with studies from other countries, including
Finland [28], Norway [29], the UK [23] and the US
[13]. Taken in context, our observations suggest thatRA patients may be a suitable target population for
anti-resorptive agents.
However, we observed a lower than expected rate of
hip fracture in our RA population. This observation
may be explained by the unmeasured severity of disease;
more severe RA disease is known to increase the likeli-
hood of a sedentary lifestyle, which might negatively in-
fluence lean mass and muscle strength [30] and increase
falls risk, with a subsequent increase in fracture risk. In-
deed, it has been reported that a fear of falling is com-
mon in RA populations [31]. Alternatively, and given
that we captured all RA patients, some of whom may be
early in the disease pathogenesis, it is likely that hip
fracture may be associated with later or long standing
disease [21], a greater severity of RA disease [32], a pro-
longed use of medications associated with RA, or other
unmeasured factors. We did not ascertain reasons for
fracture in the RA or non-RA population; however, inci-
dent hip fractures in our controls may plausibly be re-
lated to increased risk taking behavior, or in the very
least, less sedentary behavior when compared to the RA
population. Whilst an increased hip fracture incidence
is often reported in RA populations compared to non-RA
populations, some studies have acknowledged that their
RA sample included a higher proportion of osteoporotic
patients, represented by low bone mineral density, com-
pared to the general population [14]; ours was a com-
prehensive study of an entire region.
Our study has some strength. We derived our non-RA
population at risk from official 1996 Census counts of
the ABS [15]. By use of the GOS-FracGrid, which docu-
ments incident fractures for the entire BSD region
ascertained from radiological reports, we were therefore
able to directly calculate the fracture incidence rates for
the RA and non-RA populations. Whilst other studies
have examined associations between RA and fractures
at various sites, a unique feature of our work is that our
fracture ascertainment methodology enabled us to identify
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at all skeletal sites. Furthermore the fractures investigated
in our study were not self-reported, nor did they require
hospital admission (as we were not reliant on hospital ad-
mission and/or discharge data). Our study also has some
limitations. Whereas our validated method of identifying
fractures from original radiological reports tested the pos-
sibility of false-positives, we cannot exclude the possibility
that false-negatives (failure to report a fracture) may exist.
False-negatives in radiology reporting would likely result
in an underestimation of the association between fracture
incidence and RA; for instance not all fractures of the fin-
gers or toes may undergo radiography. Our identification
of RA patients would exclude those residents of the BSD
who may have chosen to visit rheumatologists outside
the region for ongoing care; however, rheumatologists
practicing at the Barwon Rheumatology Service suggest
that the number of RA sufferers in the region whom they
had not seen for at least one consultation would likely
be negligible. It is plausible that we may have missed
fractures that occurred outside the BSD; a factor that
may have influenced our lower than expected rate of hip
fractures in the RA population. Given our sample size,
and the wide age strata necessarily employed for analyses,
we cannot exclude that residual confounding may influ-
ence our results. Finally, we were unable to account for
medication use, the duration of RA, or co-morbidities,
which may influence the observed associations. Although
it has been suggested that glucocorticoid use may not
confound the association between fracture and RA
[23], indeed glucocorticoid use has been documented
as both negatively and positively influencing bone
damage.Conclusion
In conclusion, our data indicate that women with RA have
an increased risk of fracture compared to women without
RA. Furthermore, fractures are more likely to occur at
major osteoporotic sites such as vertebral, hip or Colles’,
than at sites adjacent to the joints affected by RA. In light
of these data, we suggest that RA patients may be a suit-
able target population for anti-resorptive agents such as
bisphosphonates, however we suggest that larger studies
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